GlassScriptPhysician profile
Tahir Yaqub
NPI 1326077280
$1,166.29
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $149 · 2021: $128 · 2022: $305 · 2023: $280 · 2024: $61.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.98 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $108.63 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $100.05 | 2022-2023 | |
| Lilly USA, LLC | $74.02 | 2020-2024 | Mounjaro |
| Sanofi Pasteur INC. | $61.05 | 2019-2024 | |
| Baxter Healthcare | $56.60 | 2023 | Hillrom - Life 2000 Ventilation System |
| Pfizer INC. | $52.81 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $51.07 | 2020-2022 | |
| Philips North America LLC | $49.53 | 2019-2023 | |
| Exact Sciences Corporation | $47.47 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $45.77 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $45.35 | 2021 | |
| Glaxosmithkline, LLC. | $44.77 | 2019-2022 | |
| Qiagen, LLC | $43.28 | 2022-2023 | |
| Shield Therapeutics INC | $39.32 | 2023 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.07 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.40 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $28.80 | 2019-2020 | |
| Edwards Lifesciences Corporation | $27.19 | 2022 | |
| Amarin Pharma, INC. | $27.15 | 2019-2020 | |
| Alkermes, INC. | $24.02 | 2020 | |
| Electromed, INC. | $19.84 | 2023 | Smartvest |
| Lundbeck LLC | $19.79 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.04 | 2022 | |
| Acadia Pharmaceuticals INC | $16.97 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $15.19 | 2022 | |
| Novo Nordisk INC | $14.45 | 2023 | |
| Genentech USA, INC. | $13.97 | 2020 | |
| Seqirus USA INC | $13.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.38 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.96 | 2022 | |
| Concordia Pharmaceuticals INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tahir Yaqub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.